Clinical trials: Environmental Exposures
Seasonal Allergic Rhinitis
This Study Contains an Active Drug Treatment Group With Mometasone Furoate Nasal Spray and a Placebo (Dummy) Treatment Group for Seasonal Allergic Rhinitis (SAR). (Study P05073)(COMPLETED)
The purpose of this study is to evaluate how well mometasone furoate nasal spray (MFNS) works to relieve SAR symptoms compared to Placebo when symptoms are induced in a chamber setting.
- Trial name
- NCT00491504
- Testing
- Mometasone Furoate Nasal Spray
- Volunteers
- 310 people
- Sponsor
- Organon and Co
Seasonal Allergic Rhinitis
Safety, Pharmacokinetics, and Efficacy of Bepotastine Besilate Nasal Product After Ragweed Pollen Exposure in an Environmental Chamber
The purpose of this study is to examine the safety and efficacy of bepotastine besilate nasal product in seasonal allergic rhinitis patients.
- Trial name
- NCT01222299
- Testing
- bepotastine besilate nasal product - low dose, bepotastine besilate nasal product - medium dose, bepotastine besilate nasal product - high dose
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Bausch & Lomb Incorporated
Endocrine Disrupting Chemicals, Environmental Exposure
Personalized Mobile Intervention to Reduce Exposure to Endocrine Disrupting Chemicals in Adults of Child-Bearing Age
The goal of this intervention study is to determine to what extent the Million Marker (MM) program reduces users' endocrine disruption chemical (EDC) exposure levels and changes their environmental health awareness and behaviors.
- Conditions
- Endocrine Disrupting Chemicals, Environmental Exposure, Health Literacy, Bisphenol A
- Trial name
- NCT05780047
- Testing
- Mail-in Urine Test for EDCs
- Where
- United States
- Volunteers
- 434 people, healthy volunteers welcome
- Sponsor
- Million Marker Wellness, Inc.
Allergic Conjunctivitis
The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.
The INVIGORATE Trial: A Randomized, Double-masked, Crossover Design, Phase 3 Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.
- Trial name
- NCT04207736
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution
- Where
- Canada
- Volunteers
- 95 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Environmental Exposure
Ultralow Dose PAH Binary Mixture Study
Evaluation of the pharmacokinetics for [14C]-benzo[a]pyrene ([14C]-BaP) and metabolites in plasma and urine over 48 hours following a 50 ng dose (5.4 nCi) alone or with 1250 ng phenanthrene.
- Trial name
- NCT03631667
- Testing
- [14C]-benzo[a]pyrene, [14C]-benzo[a]pyrene plus phenanthrene
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Oregon State University
Allergic Conjunctivitis
Assessment of Alcon's Ocular Image Quantification System
The purpose of this study was to evaluate ocular responses with different allergen provocation methods.
- Trial name
- NCT01282138
- Testing
- Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol), Dextran 70 0.1%, hydroxypropyl methylcellulose 0.3% (Tears Naturale II)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Alcon Research
Nicotine Dependence, Smoking, Cigarette
Isradipine Enhancement of Virtual Reality Cue Exposure for Smoking Cessation
The proposed study represents a crucial and important stage in translating basic research to strategies for treating nicotine dependence.
- Conditions
- Nicotine Dependence, Smoking, Cigarette, Smoking Cessation, Smoking Behaviors
- Trial name
- NCT03083353
- Testing
- Isradipine, Cue Exposure
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Jasper A. Smits
Allergic Conjunctivitis
The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis
The INVIGORATE 2 Trial: A single-center, randomized, double-masked, crossover design, vehicle-controlled, Phase 3 clinical trial to assess the efficacy and safety of reproxalap ophthalmic solution (0.25%) compared to vehicle in…
- Trial name
- NCT05234554
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution
- Where
- Canada
- Volunteers
- 131 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Nasal Allergies, Allergies
Safety and Efficacy of AL-53817 Nasal Spray Solution
The purpose of this study was to determine the maximum tolerated dose of AL-53817 (Stage A) and evaluate the safety and efficacy of AL-53817 for the treatment of allergic rhinitis (Stage B).
- Trial name
- NCT01454505
- Testing
- AL-53817 nasal spray solution, Vehicle nasal spray
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Dry Eye Syndromes
Evaluation of the Safety and Effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator in Patients With Dry Eye
The purpose of this study was to evaluate the safety and effectiveness of the Intranasal Tear Neurostimulator applied intranasally compared with the same device applied extranasally (control) in treating the symptoms of dry eye…
- Trial name
- NCT02313454
- Testing
- Intranasal Tear Neurostimulator
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Allergan
Allergic Conjunctivitis
Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for Allergic Conjunctivitis
The purpose of this study is to evaluate two investigational ophthalmic solutions for reduction in ocular redness in subjects with allergic conjunctivitis.
- Trial name
- NCT02079649
- Testing
- AL-53817 Ophthalmic Solution, 0.1%, AL-78843 Ophthalmic Solution, 0.03%, Dexamethasone Ophthalmic Suspension, 0.1%
- Volunteers
- 224 people
- Sponsor
- Alcon Research
Allergic Rhinitis
An Efficacy Study of JNJ-39220675 and Pseudoephedrine in Participants With Allergic Rhinitis
The purpose of this study is to evaluate the relative efficacy of JNJ- 39220675 and pseudoephedrine compared to placebo (medication with no active ingredients) in participants with allergic rhinitis (inflammation of the nose due…
- Trial name
- NCT00804687
- Testing
- JNJ-39220675, Pseudoephedrine
- Where
- Canada
- Volunteers
- 53 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Asthma, Environmental Exposure
Home Air Quality Impact for Adults With Asthma
The purposes of this study are to determine the practicality of using home indoor air quality monitoring and a smartphone app to identify home air quality changes and how these changes affect adults with asthma.
- Conditions
- Asthma, Environmental Exposure, Home Environment Related Disease
- Trial name
- NCT05224076
- Testing
- Home Air Quality
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of Kansas Medical Center
Conjunctivitis, Allergic
A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber
An Exploratory Clinical Trial Evaluating Reproxalap Ophthalmic Solutions (0.25% and 0.5%) in Subjects with Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber (EEC)
- Trial name
- NCT03709121
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Health Knowledge, Attitudes, Practice
Impacts of Clinician-Mediated Report-Back
The study trains clinicians to return personal exposure results to study participants in pregnancy cohorts, and measures outcomes for environmental health literacy for both clinicians and study participants.
- Trial name
- NCT06074159
- Testing
- In-clinic report-back
- Where
- 2 sites in United States, Puerto Rico
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- Silent Spring Institute
Asthma
A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma
This was a 3-center, randomized, double-blind, parallel-group, placebo-controlled study with a 16-week treatment phase to determine whether subcutaneous omalizumab, compared with placebo, reduces the degree of bronchoconstriction…
- Trial name
- AERO (NCT00495612)
- Testing
- Omalizumab
- Volunteers
- 69 people
- Sponsor
- Genentech, Inc.
Lung Diseases, Medication Compliance
Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program
The purpose of this study is to understand why patients in the World Trade Center program have continuing breathing problems. This study will improve investigators understanding of breathing problems among individuals with World…
- Trial name
- NCT02024204
- Testing
- Fluticasone propionate 230mcg for 3 Months, Current Treatment or no treatment, Salmeterol 21mcg for 3 Months
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- NYU Langone Health
Dry Eye Syndromes
Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation
This study evaluates the safety and effectiveness of the Intranasal Tear Neurostimulator applied intranasally (active) compared with the same device applied extranasally (control) relating to symptoms of dry eye exacerbated by…
- Trial name
- NCT02910713
- Testing
- Intranasal Tear Neurostimulator
- Where
- 3 sites in United States
- Volunteers
- 185 people
- Sponsor
- Allergan
Children, Only, Risk Reduction
Reducing Pesticide Exposures in Child Care Centers
A randomized control study was conducted to reduce the exposure to pesticides in child care centers. A 7-month child care health consultant-led integrated pest management (IPM) intervention was conducted in 85 child care centers…
- Conditions
- Children, Only, Risk Reduction, Environmental Exposure
- Trial name
- HCES (NCT03319927)
- Testing
- Changes in pesticide exposure, IPM Practices, Educational Workshops
- Where
- United States
- Volunteers
- 987 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Skin Cancer, Occupational Exposure
Virtual Sun Safe Workplaces Ph II (SSW Works)
Americans who work outdoors are exposed to an extreme amount of solar ultraviolet radiation over a lifetime that substantially increases their risk for developing skin cancer.
- Trial name
- NCT05774600
- Testing
- SSW Works, Minimal Information Control
- Where
- United States
- Volunteers
- 543 people, healthy volunteers welcome
- Sponsor
- Klein Buendel, Inc.